{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:39:43Z","timestamp":1775561983116,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1ZIAAI001179-01"],"award-info":[{"award-number":["1ZIAAI001179-01"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient simian adenovirus\u2013vectored vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first published full-length sequence (Wuhan-1). AZD1222 has been shown to have 74% vaccine efficacy against symptomatic disease in clinical trials. However, variants of concern (VoCs) have been detected, with substitutions that are associated with a reduction in virus neutralizing antibody titer. Updating vaccines to include S proteins of VoCs may be beneficial, even though current real-world data is suggesting good efficacy following boosting with vaccines encoding the ancestral S protein. Using the Syrian hamster model, we evaluate the effect of a single dose of AZD2816, encoding the S protein of the Beta VoC, and efficacy of AZD1222\/AZD2816 as a heterologous primary series against challenge with the Beta or Delta variant. Minimal to no viral sgRNA could be detected in lungs of vaccinated animals obtained at 3- or 5- days post inoculation, in contrast to lungs of control animals. In Omicron-challenged hamsters, a single dose of AZD2816 or AZD1222 reduced virus shedding. Thus, these vaccination regimens are protective against the Beta, Delta, and Omicron VoCs in the hamster model.<\/jats:p>","DOI":"10.1038\/s41467-022-32248-6","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T05:07:40Z","timestamp":1659935260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-6359","authenticated-orcid":false,"given":"Neeltje","family":"van Doremalen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-850X","authenticated-orcid":false,"given":"Danielle R.","family":"Adney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor A.","family":"Saturday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-472X","authenticated-orcid":false,"given":"Robert J.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude Kwe","family":"Yinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4450-5911","authenticated-orcid":false,"given":"Nazia","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-8672","authenticated-orcid":false,"given":"Joseph","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ulaszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Belij-Rammerstorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-6177","authenticated-orcid":false,"given":"Greg","family":"Saturday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7958-6961","authenticated-orcid":false,"given":"Alexandra J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-2266","authenticated-orcid":false,"given":"Dalan","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-162X","authenticated-orcid":false,"given":"Colin A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-3196","authenticated-orcid":false,"given":"Vincent J.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"32248_CR1","doi-asserted-by":"crossref","unstructured":"Zhu, N. et al. A Novel Coronavirus from patients with Pneumonia in China, 2019. New Engl. J. Med. 382, 727\u2013733 (2020).","DOI":"10.1056\/NEJMoa2001017"},{"key":"32248_CR2","doi-asserted-by":"publisher","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature https:\/\/doi.org\/10.1038\/s41586-020 (2020).","DOI":"10.1038\/s41586-020"},{"key":"32248_CR3","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/ (2022)."},{"key":"32248_CR4","doi-asserted-by":"publisher","first-page":"eaba8399","DOI":"10.1126\/sciadv.aba8399","volume":"6","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen, N. et al. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci. Adv. 6, eaba8399 (2020).","journal-title":"Sci. Adv."},{"key":"32248_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0029-1","volume":"2","author":"VJ Munster","year":"2017","unstructured":"Munster, V. J. et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. npj Vaccines 2, 28 (2017).","journal-title":"npj Vaccines"},{"key":"32248_CR6","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature https:\/\/doi.org\/10.1038\/s41586-020-2622-0 (2020).","DOI":"10.1038\/s41586-020-2622-0"},{"key":"32248_CR7","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 385, 2348\u20132360 (2021).","journal-title":"N. Engl. J. Med."},{"key":"32248_CR8","doi-asserted-by":"publisher","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet S0140673620326611 https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1. (2020)","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"32248_CR9","doi-asserted-by":"publisher","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. NEJMoa2035389 https:\/\/doi.org\/10.1056\/NEJMoa2035389 (2020).","DOI":"10.1056\/NEJMoa2035389"},{"key":"32248_CR10","doi-asserted-by":"publisher","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. NEJMoa2034577 https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","DOI":"10.1056\/NEJMoa2034577"},{"key":"32248_CR11","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"32248_CR12","unstructured":"Zhang, Y.-Z. Novel 2019 coronavirus genome. https:\/\/virological.org\/t\/novel-2019-coronavirus-genome\/319."},{"key":"32248_CR13","doi-asserted-by":"crossref","unstructured":"AstraZeneca. Two billion doses of AstraZeneca\u2019s COVID-19 vaccine supplied to countries across the world less than 12 months after first approval. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval.html (2022).","DOI":"10.1007\/s40278-022-22875-6"},{"key":"32248_CR14","doi-asserted-by":"publisher","unstructured":"Lipsitch, M., Krammer, F., Regev-Yochay, G., Lustig, Y. & Balicer, R. D. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-021-00662-4 (2021).","DOI":"10.1038\/s41577-021-00662-4"},{"key":"32248_CR15","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/ (2022)."},{"key":"32248_CR16","doi-asserted-by":"publisher","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. The Lancet Microbe S2666524721002676 https:\/\/doi.org\/10.1016\/S2666-5247(21)00267-6 (2021).","DOI":"10.1016\/S2666-5247(21)00267-6"},{"key":"32248_CR17","doi-asserted-by":"publisher","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell S0092867421002269 https:\/\/doi.org\/10.1016\/j.cell.2021.02.037 (2021).","DOI":"10.1016\/j.cell.2021.02.037"},{"key":"32248_CR18","doi-asserted-by":"publisher","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01270-4 (2021).","DOI":"10.1038\/s41591-021-01270-4"},{"key":"32248_CR19","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Neutralizing Activity of BNT162b2-Elicited Serum\u2014Preliminary Report. N. Engl. J. Med. NEJMc2102017 https:\/\/doi.org\/10.1056\/NEJMc2102017 (2021).","DOI":"10.1056\/NEJMc2102017"},{"key":"32248_CR20","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41564-021-00974-0","volume":"6","author":"L Dupont","year":"2021","unstructured":"Dupont, L. et al. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat. Microbiol. 6, 1433\u20131442 (2021).","journal-title":"Nat. Microbiol."},{"key":"32248_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"32248_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","volume":"397","author":"KRW Emary","year":"2021","unstructured":"Emary, K. R. W. et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 397, 1351\u20131362 (2021).","journal-title":"Lancet"},{"key":"32248_CR23","doi-asserted-by":"crossref","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 385, 585\u2013594 (2021).","DOI":"10.1056\/NEJMoa2108891"},{"key":"32248_CR24","doi-asserted-by":"publisher","unstructured":"Spencer, A. J. et al. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies. http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.06.08.447308 (2021) https:\/\/doi.org\/10.1101\/2021.06.08.447308.","DOI":"10.1101\/2021.06.08.447308"},{"key":"32248_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/v14030543","volume":"14","author":"ZA Weishampel","year":"2022","unstructured":"Weishampel, Z. A. et al. OraSure InteliSwabTM Rapid antigen test performance with the SARS-CoV-2 variants of concern\u2014Alpha, Beta, Gamma, Delta, and Omicron. Viruses 14, 543 (2022).","journal-title":"Viruses"},{"key":"32248_CR26","doi-asserted-by":"publisher","unstructured":"Mykytyn, A. Z. et al. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants. http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.02.23.481644 (2022) https:\/\/doi.org\/10.1101\/2022.02.23.481644.","DOI":"10.1101\/2022.02.23.481644"},{"key":"32248_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","volume":"603","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687\u2013692 (2022).","journal-title":"Nature"},{"key":"32248_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26178-y","volume":"12","author":"RJ Fischer","year":"2021","unstructured":"Fischer, R. J. et al. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Nat. Commun. 12, 5868 (2021).","journal-title":"Nat. Commun."},{"key":"32248_CR29","doi-asserted-by":"publisher","first-page":"eabj3789","DOI":"10.1126\/scitranslmed.abj3789","volume":"13","author":"LH Tostanoski","year":"2021","unstructured":"Tostanoski, L. H. et al. Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. Sci. Transl. Med. 13, eabj3789 (2021).","journal-title":"Sci. Transl. Med."},{"key":"32248_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-021-03732-8","volume":"596","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature 596, 423\u2013427 (2021).","journal-title":"Nature"},{"key":"32248_CR31","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s41590-021-01021-0","volume":"22","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nat. Immunol. 22, 1306\u20131315 (2021).","journal-title":"Nat. Immunol."},{"key":"32248_CR32","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2024671 (2020).","DOI":"10.1056\/NEJMoa2024671"},{"key":"32248_CR33","doi-asserted-by":"publisher","unstructured":"Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies, and protection against Omicron. http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.02.03.479037 (2022) https:\/\/doi.org\/10.1101\/2022.02.03.479037.","DOI":"10.1101\/2022.02.03.479037"},{"key":"32248_CR34","doi-asserted-by":"publisher","unstructured":"Hawman, D. W. et al. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in na\u00efve hamsters compared to ancestral vaccine. http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.01.31.478520 (2022) https:\/\/doi.org\/10.1101\/2022.01.31.478520.","DOI":"10.1101\/2022.01.31.478520"},{"key":"32248_CR35","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","volume":"586","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578\u2013582 (2020).","journal-title":"Nature"},{"key":"32248_CR36","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","volume":"398","author":"A Flaxman","year":"2021","unstructured":"Flaxman, A. et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 398, 981\u2013990 (2021).","journal-title":"Lancet"},{"key":"32248_CR37","doi-asserted-by":"publisher","unstructured":"Abdelnabi, R. et al. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.24.474086 (2021) https:\/\/doi.org\/10.1101\/2021.12.24.474086.","DOI":"10.1101\/2021.12.24.474086"},{"key":"32248_CR38","doi-asserted-by":"publisher","unstructured":"van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques. http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.01.09.426058 (2021) https:\/\/doi.org\/10.1101\/2021.01.09.426058.","DOI":"10.1101\/2021.01.09.426058"},{"key":"32248_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00301-y","volume":"6","author":"JEM van der Lubbe","year":"2021","unstructured":"van der Lubbe, J. E. M. et al. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. npj Vaccines 6, 39 (2021).","journal-title":"npj Vaccines"},{"key":"32248_CR40","doi-asserted-by":"publisher","unstructured":"Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature (2020) https:\/\/doi.org\/10.1038\/s41586-020-2607-z.","DOI":"10.1038\/s41586-020-2607-z"},{"key":"32248_CR41","doi-asserted-by":"crossref","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045 (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045"},{"key":"32248_CR42","doi-asserted-by":"crossref","unstructured":"Rothe, C. et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New Engl. J. Med. 382, 970\u2013971 (2020).","DOI":"10.1056\/NEJMc2001468"},{"key":"32248_CR43","doi-asserted-by":"publisher","first-page":"e4249","DOI":"10.21769\/BioProtoc.4249","volume":"11","author":"N Thakur","year":"2021","unstructured":"Thakur, N., Gallo, G., Elreafey, A. M. E. & Bailey, D. Production of recombinant replication-defective lentiviruses bearing the SARS-CoV or SARS-CoV-2 attachment spike glycoprotein and their application in receptor tropism and neutralisation assays. Bio Protoc. 11, e4249 (2021).","journal-title":"Bio Protoc."},{"key":"32248_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17409-9","volume":"11","author":"PF McKay","year":"2020","unstructured":"McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).","journal-title":"Nat. Commun."},{"key":"32248_CR45","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1126\/science.1097211","volume":"305","author":"DJ Smith","year":"2004","unstructured":"Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371\u2013376 (2004).","journal-title":"Science"},{"key":"32248_CR46","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.1256427","volume":"346","author":"JM Fonville","year":"2014","unstructured":"Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Science 346, 996\u20131000 (2014).","journal-title":"Science"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32248-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:25:26Z","timestamp":1669296326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32248-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32248"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32248-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1343927\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"19 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C.G. is a co-founder and stock-holder of Vaccitech and named as an inventor on a patent covering the use of ChAdOx1-vector-based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and Vaccitech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor Vaccitech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4610"}}